On Jul. 29, 2021, the University of Oxford’s and AstraZeneca announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine had been released, to more than 170 countries, marking a key milestone as part of the University and AstraZenecaﾒs joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

AstraZeneca, with their extensive world-wide development and manufacturing capabilities, have been able to have the vaccine approved and licenced for use in over 170 countries, with over 20 manufacturing sites across the world, including the Serum Institute of India, working together to release the one billion doses worldwide.

As the manufacturing of adeno-virus vector vaccines is complex and requires significant investment in infrastructure and expertise to ensure the safety and quality of the vaccine, we are working together with AstraZeneca to ensure that significant technology transfer happens between the global manufacturing sites and their supply chains.